Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (DE:8EM)
FRANKFURT:8EM
Holding DE:8EM?
Track your performance easily
See the Price Targets and Ratings of:
8EM Analyst Ratings
Hold
4 Buy
11 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
8EM Stock 12 Month Forecast
Average Price Target
€3.97
▲(214.23% Upside)
| Highest Price Target€7.72 | Average Price Target€3.97 | Lowest Price Target€0.96 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Clear Street
Initiated
12/18/24
Evercore ISI
Reiterated
12/16/24
J.P. Morgan
Downgraded
12/16/24
Truist Financial
Downgraded
12/13/24
Chardan Capital
Downgraded
12/13/24
Robert W. Baird
Reiterated
12/13/24
Morgan Stanley
Reiterated
12/13/24
Barclays
Reiterated
12/13/24
TD Cowen
Assigned
12/13/24
Wells Fargo
Downgraded
12/13/24
Stifel Nicolaus
€2.89
Hold
129.37%
Upside
Downgraded
12/13/24
Editas Medicine: Navigating Uncertainty with a Hold Rating Amid Strategic Shifts and Development Challenges
JonesTrading
―
Hold
―
Downgraded
12/13/24
Editas Medicine Maintains Hold Rating Amid Strategic Shifts and Financial Challenges
Leerink Partners
€7.72→€0.96
Hold
-23.54%
Downside
Reiterated
12/12/24
Analysts Offer Insights on Healthcare Companies: Affimed (NASDAQ: AFMD), Editas Medicine (NASDAQ: EDIT) and Trevi Therapeutics (NASDAQ: TRVI)
RBC Capital
€4.82→€3.86
Hold
205.82%
Upside
Reiterated
12/12/24
RBC Capital Sticks to Its Hold Rating for Editas Medicine (EDIT)
Bank of America Securities
―
Sell
―
Downgraded
11/22/24
Bank of America Securities downgrades Editas Medicine (EDIT) to a Sell
Best Analysts Covering Editas Medicine
Which Analyst Should I Follow If I Want to Buy DE:8EM and Sell After:
1 Month
xxx
Success Rate
4/14 ratings generated profit
Average Return
-2.99%
assigned a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 28.57% of your transactions generating a profit, with an average return of -2.99% per trade.
3 Months
xxx
Success Rate
4/14 ratings generated profit
Average Return
-9.85%
assigned a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -9.85% per trade.
1 Year
Success Rate
5/14 ratings generated profit
Average Return
-8.36%
assigned a buy rating 9 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -8.36% per trade.
2 Years
xxx
Success Rate
7/14 ratings generated profit
Average Return
+19.04%
assigned a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +19.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
8EM Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
10
7
11
13
16
Buy
2
2
3
3
4
Hold
16
10
11
12
20
Sell
0
0
0
1
2
Strong Sell
0
0
0
0
0
total
28
19
25
29
42
Each month's total comprises the sum of three months' worth of ratings.
8EM Financial Forecast
8EM Stock Forecast FAQ
What is DE:8EM’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is €3.97.
What is DE:8EM’s upside potential, based on the analysts’ average price target?
Editas Medicine Inc has 214.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Editas Medicine Inc a Buy, Sell or Hold?
Editas Medicine Inc has a consensus rating of Hold, which is based on 4 buy ratings, 11 hold ratings and 2 sell ratings.
What is Editas Medicine Inc’s share price target?
The average share price target for Editas Medicine Inc is €3.97. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €7.72 ,and the lowest forecast is €0.96. The average share price target represents 214.23% Increase from the current price of €1.262.
The highest analyst share price target is €7.72 ,and the lowest forecast is €0.96. The average share price target represents 214.23% Increase from the current price of €1.262.
What do analysts say about Editas Medicine Inc?
Editas Medicine Inc’s analyst rating consensus is a Hold. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of Editas Medicine Inc?
To buy shares of DE:8EM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.